This inventor holds 2 USPTO granted patents. Top assignee: Hoechst Aktiengesellschaft. Active years: 1977-1979.
Location History:
- Kelkheim, Taunus, DE (1977)
- Kelkheim, DE (1979)
Company Filing History:
Years Active: 1977-1979
Title: Heinrich Rolly: Innovator in Antiviral Compounds
Introduction
Heinrich Rolly is a notable inventor based in Kelkheim, Germany. He has made significant contributions to the field of antiviral research, holding a total of 2 patents. His work focuses on developing compounds that combat viral diseases, showcasing his commitment to improving health outcomes.
Latest Patents
Rolly's latest patents include innovative compounds that are designed to be effective against viruses. One of his notable inventions is an antiviral polymer, specifically Poly(acrylic acid) salts with unique structural characteristics. These salts are particularly useful for combatting virus diseases. Another significant patent involves 5-Cyano-thiophen-2-aldehyde-isothiosemicarbazones, which are described along with a process for their manufacture. These novel compounds are active against viruses, making them suitable for the prophylaxis and therapy of corresponding infections in both humans and animals.
Career Highlights
Heinrich Rolly is associated with Hoechst Aktiengesellschaft, a prominent company in the pharmaceutical and chemical sectors. His work at Hoechst has allowed him to focus on innovative research and development in antiviral therapies. Rolly's contributions have been instrumental in advancing the understanding and treatment of viral infections.
Collaborations
Rolly has collaborated with esteemed colleagues such as Karlheinz Burg and Arthur Neufahrt. These partnerships have fostered a collaborative environment that enhances the research and development of antiviral compounds.
Conclusion
Heinrich Rolly's work in the field of antiviral research exemplifies the impact of innovation on public health. His patents and collaborations reflect a dedication to combating viral diseases through scientific advancement. His contributions continue to pave the way for future developments in antiviral therapies.